Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma

• Published in: Head & neck Vol. 39; no. 7; pp. 1327 - 1332
• Main Authors: Ko, Hui‐Hsin, Cheng, Shih‐Lung, Lee, Jang‐Jaer, Chen, Hsin‐Ming, Kuo, Mark Yen‐Ping, Cheng, Shih‐Jung
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2017
• Subjects: Adult; Aged; AKR1B10; Aldehyde Reductase - genetics; Aldo-keto reductase; areca quid; Biomarkers, Tumor - genetics; Biopsy, Needle; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Chewing; Clinical trials; Cohort Studies; Databases, Factual; Detoxification; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Head and neck; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms - genetics; Mouth Neoplasms - mortality; Mouth Neoplasms - pathology; Mucosa; Multivariate Analysis; Neck; Oral cancer; Oral carcinoma; Oral squamous cell carcinoma; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Squamous cell carcinoma; Survival Analysis; Taiwan; Tumorigenesis; AKR1B10; prognosis; areca quid; oral cancer
• ISSN: 1043-3074; 1097-0347
• DOI: 10.1002/hed.24759

ABSTRACT Background Aldo‐keto reductase family 1 member B10 (AKR1B10) is implicated in xenobiotic detoxification and has disparate functions in tumorigenesis that are dependent on the cell types. The purpose of this study was to investigate the clinicopathological significance of AKR1B10 as a prognostic marker for oral squamous cell carcinomas (OSCCs). Methods AKR1B10 protein expression was analyzed by immunohistochemistry in 77 patients with OSCC. Results The AKR1B10 labeling score for OSCCs (1.16 ± 1.14) was significantly higher than that for normal oral mucosa (0.10 ± 0.23; p < .0001). High expression of AKR1B10 significantly correlated with large tumor size (p = .041), advanced TNM classification (p = .037), and patient's areca quid chewing habit (p = .025). Multivariate analysis revealed that high AKR1B10 labeling score >1.16 (hazard ratio, 3.647; p = .001) significantly correlated with mortality. Conclusion AKR1B10 overexpression is an independent poor prognostic biomarker for OSCC. AKR1B10 inhibitors may be promising in clinical trials against OSCC. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1327–1332, 2017